William Blair Forecasts NeoGenomics Q1 Earnings

NeoGenomics, Inc. (NASDAQ:NEO) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for NeoGenomics in a report issued on Tuesday, February 18th. William Blair analyst A. Brackmann forecasts that the medical research company will post earnings of $0.00 per share for the quarter. The consensus estimate for NeoGenomics’ current full-year earnings is ($0.05) per share. William Blair also issued estimates for NeoGenomics’ Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.03 EPS.

A number of other research firms also recently commented on NEO. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Bank of America reduced their target price on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday. Jefferies Financial Group began coverage on NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price on the stock. Needham & Company LLC reduced their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, The Goldman Sachs Group reduced their target price on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, NeoGenomics currently has an average rating of “Moderate Buy” and an average target price of $19.80.

NeoGenomics Stock Performance

NASDAQ NEO opened at $11.10 on Friday. The stock’s fifty day moving average is $15.28 and its two-hundred day moving average is $15.49. The firm has a market capitalization of $1.43 billion, a P/E ratio of -17.90 and a beta of 1.23. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. NeoGenomics has a fifty-two week low of $10.69 and a fifty-two week high of $19.11.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). The company had revenue of $172.00 million for the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%.

Institutional Investors Weigh In On NeoGenomics

Institutional investors and hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new stake in shares of NeoGenomics in the 4th quarter valued at $26,000. Versant Capital Management Inc raised its holdings in shares of NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,142 shares during the period. Quarry LP purchased a new stake in NeoGenomics during the 3rd quarter worth about $40,000. Blue Trust Inc. increased its holdings in NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after purchasing an additional 987 shares during the period. Finally, Sterling Capital Management LLC increased its holdings in NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock worth $61,000 after purchasing an additional 3,289 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.